Why are most APIs sourced from China and India?

API production in China and India has been built over decades on scale, integrated raw material supply chains, and highly technical workforces. This has created structural advantages and concentration: approximately two-thirds of API certificates for the EU market are held by manufacturers in these two countries. While this provides cost efficiency, it creates inherent geographic concentration risk.

What are the main supply chain vulnerabilities in API sourcing?

Key vulnerabilities include: geographic concentration limiting supplier options, lack of transparency in upstream supply chains, quality inconsistencies (nitrosamine and elemental impurity control issues), regulatory risks (FDA import alerts and warning letters), limited global capacity, lengthy supplier qualification processes, and dependencies on critical excipients and packaging materials. Additionally, 44% of drugs in shortage have at least one key starting material sourced from a single country.

Is dual sourcing sufficient to address API supply chain risk?

No. According to industry experts, simply identifying a second supplier is insufficient. The alternative source must be appropriately qualified, meet required quality and regulatory standards, and be maintained at a readiness level allowing rapid activation during disruption. Additionally, supply chain professionals must look beyond the API itself to identify critical excipients, processing aids, and packaging materials that may create equally significant bottlenecks.

What strategies can companies implement to build API supply chain resilience?

Recommended strategies include: conducting structured supply chain risk assessments to identify business-critical materials and realistic qualification timelines, building evidence-based maps of every manufacturing node to identify hidden Tier 2 and Tier 3 dependencies, implementing robust demand forecasting and visibility systems, establishing appropriate risk mitigation strategies tailored to acceptable risk levels, maintaining close supplier relationships, and leveraging external data partnerships for dynamic scenario-based resilience planning rather than static supplier mapping.

How much does pharmaceutical supply chain disruption cost the industry?

Supply chain disruptions cost the pharmaceutical industry an estimated $184 billion annually. Sterile injectables account for 71% of U.S. drug shortages, highlighting that upstream fragility in API and starting material production, rather than finished-dose manufacturing, is where the majority of supply chain disruptions originate.

Procurement

High Impact

Pharma API Sourcing: How to Build Resilience Against Geopolitical Risk

Nov 3, 2026

Get tomorrow's supply chain signal

Daily supply-chain brief. Free, unsubscribe anytime.

The signal

Pharmaceutical companies face critical vulnerabilities in Active Pharmaceutical Ingredient (API) sourcing due to geographic concentration in China and India, which account for approximately two-thirds of EU API certificates. These structural dependencies expose manufacturers to geopolitical disruption, regulatory changes, quality issues, and trade restrictions. Supply chain disruptions cost the industry an estimated $184 billion annually, with 44% of drugs in shortage sourced from a single country.

Industry leaders emphasize that traditional single-source models are no longer viable. The solution requires three interconnected strategies: building comprehensive supply chain visibility to identify hidden dependencies two or three tiers deep, qualifying realistic alternative suppliers before disruption occurs, and moving beyond simple dual-sourcing to include scenario-based resilience planning. Companies must conduct rigorous supply chain risk assessments to distinguish between unavoidable single-source dependencies and those created by historical sourcing decisions.

For supply chain professionals, this represents a structural shift in how APIs should be sourced. Investment in supplier relationship management, ongoing qualification, and external data partnerships for dynamic resilience planning are no longer optional but essential to business continuity. Organizations lacking visibility into their upstream networks face material risk of extended shortages and regulatory import alerts.

How this affects:

Lineage Logistics

Open the full daily intelligence brief · Pulse 80

#api-sourcing

#pharmaceutical-supply-chain

#supply-chain-resilience

#dual-sourcing

#geopolitical-risk

#china-india-concentration

#supply-chain-visibility

#supplier-qualification

#drug-shortages

#procurement-strategy

Frequently Asked Questions

What This Means for Your Supply Chain

Simulation Suggestion

immediate

What if a major Chinese API manufacturer receives an FDA import alert?

Simulate the scenario where a critical API supplier in China loses FDA approval due to quality or compliance issues, forcing immediate activation of a secondary supplier. Model the impact on product availability, lead times, and inventory levels across your portfolio if you have 60 days to transition 30% of your volume to an alternative source.

Run this scenario

Simulation Suggestion

strategic

What if you need to qualify a secondary API supplier with 6-month regulatory lead time?

Simulate the operational and financial implications of qualifying a secondary API supplier while maintaining current supply commitments. Model inventory build-up strategies, working capital impact, timeline risk, and service level implications if the primary supplier experiences a 4-week disruption during the 6-month qualification window. Evaluate whether dual sourcing breaks even on holding costs versus disruption risk.

Run this scenario

Simulation Suggestion

this month

What if new tariffs increase API import costs from India by 25%?

Model the financial and operational impact of a 25% increase in API procurement costs from India due to new trade tariffs or regulations. Analyze how this affects gross margins, pricing strategy, and the business case for pursuing nearshoring or localized sourcing alternatives. Consider the cost-benefit of qualifying secondary suppliers in alternative geographies.

Run this scenario

Go deeper:

Supply Chain Modeling Software: A Buyer's Guide

Supply chain and logistics modeling, how to evaluate modeling software, and how to choose the right model for questions like where to put a new warehouse.

Risk & DisruptionHigh Impact

Pharma Testing Under Siege: Geopolitical Chaos Threatens Drug Development

Oct 23, 2026

Risk & DisruptionHigh Impact

Manufacturing Resilience Up but Visibility Gap Remains Critical Risk

Oct 29, 2026

Demand PlanningHigh Impact

Pharmaceutical Industry Overhauls Supply Chain Planning Amid Rising Disruptions

Oct 7, 2026

Get the daily supply chain briefing

Top stories, Pulse score, and disruption alerts. No spam. Unsubscribe anytime.